- Reporters Barred from Ariad, Celgene, Cougar Roundtable?
- Amgen CEO To Shareholders: I Feel Your Pain, Too

- Amgen's Visit From The "Tooth Fairy" (By Way Of Root Canal?)

- Merck's Layoffs Show Pain Of Lower Drug Sales,Too Many Reps
- Pfizer "Re-Lighting" Chantix Ad Campaign For Smokers?
- Fixing Pfizer And Your Emails
- Former Merck CEO Prodding Industry On Drug Pricing
- Merck "Adapts" To Tredaptive Setback

- Regulatory "Risky Business" for Pharma & Biotech
- Amgen: Is "A" For Anemia Or Acquisition?
- RIM's BlackBerry Bold Is Something To Behold
- Race For White House Now A Game Of (Headless) Chicken?

- What's In A Name: Kobe And Eli Up, Roger Down--And Darren?
- Hybrid Backlash: Your Comments On My "Critical" Post
- "Major League Eating: The Game" Now On Wii (And No Calories)
- Market 360: The Best and Worst of the Week for US Equities, Commodities, Currencies, and More
- Your First Move For Monday May 12th

- Web Extra: 3 Trades For Week Ahead

- Surprise Friday: Guess The Guest!

- Lightning Round OT: Fluor, Aqua America and More

- Fed's Evans: Monetary Policy Balances Current Risks
- Deutsche Telekom May Gain Control of Greek Company
- Bonds Flat as Stock Market Looks for Direction
- IPOs in the City: Prada Vs. Ferragamo
- Sprint's Quarterly Loss Widens, Revenue Falls
- MBIA Swings to Huge Loss of $2.4 Billion
- Ford May Scrap Mercury Rather than Revive It
- HSBC Earnings, Bad Debts Rise
- Morgan Stanley Raises $4 Billion for Infrastructure
- Inflation, Housing Data Lead Busy Economic Week

![]() |
CNBC.com |
They're working on the rest of it and say it'll be completely redone by the end of this year. In the meantime, the site remains difficult to navigate in spots.
I think it's too cluttered, not all that user-friendly, and somewhat counterintuitive when it comes to finding new warnings, communications, etc. in a hurry when I'm on deadline. I look forward to surfing the new-and-improved version when it's finished.
But guess who's quasi-blogging on the new site? Yep, none other than the commish. That's right, Dr. Andrew von Eschenbach has kicked off a weekly online communication, "Andy's Take." You can check out his first installment here.
But it's a one-way thing. This will, no doubt, come as a disappointment to Dendreonians and Provenge proponents among others, but there's no link to email Andy or post comments on his "blog".
You can, however, email me--not with questions for Andy--but with your comments on the blog and all things pharma anytime: .
Time permitting, I'm happy to answer questions about facts, but please don't ask me for buy, sell, hold recommendations because I don't/won't give 'em. Thanks.
Questions? Comments?




